101 |
NCT00217425 |
Completed Has Results |
Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms |
|
- Biological: bevacizumab
- Drug: cyclophosphamide
- Drug: doxorubicin
- (and 2 more...)
|
Interventional |
Phase 2 |
- Eastern Cooperative Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 12-Month Progression-Free Survival (PFS)
- Overall Response Rate
- 3-Year Overall Survival
|
46 |
All |
18 Years and older (Adult, Senior) |
NCT00217425 |
CDR0000441194 U10CA021115 E2404 |
|
July 2006 |
April 2012 |
March 2014 |
September 22, 2005 |
May 7, 2014 |
May 7, 2014 |
- California Cancer Care, Incorporated - Greenbrae
Greenbrae, California, United States - Veterans Affairs Medical Center - Palo Alto
Palo Alto, California, United States - Front Range Cancer Specialists
Fort Collins, Colorado, United States - (and 107 more...)
|
102 |
NCT02465060 |
Recruiting |
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) |
- Advanced Malignant Solid Neoplasm
- Bladder Carcinoma
- Breast Carcinoma
- (and 47 more...)
|
- Drug: Adavosertib
- Drug: Afatinib
- Drug: Binimetinib
- (and 21 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate, defined as the percentage of patients whose tumors have a complete or partial response to treatment
- Overall survival, evaluated specifically for each drug (or step)
- Progression free survival
- Time to progression
|
6452 |
All |
18 Years and older (Adult, Senior) |
NCT02465060 |
NCI-2015-00054 EAY131 U10CA180820 U24CA196172 |
|
August 12, 2015 |
June 30, 2022 |
|
June 8, 2015 |
April 17, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - (and 1211 more...)
|
103 |
NCT02580058 |
Active, not recruiting |
A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) |
|
- Biological: avelumab
- Drug: PLD
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival (OS)
- Progression Free Survival (PFS)
- OR (Objective Response)
- (and 16 more...)
|
550 |
Female |
18 Years and older (Adult, Senior) |
NCT02580058 |
B9991009 2015-003091-77 JAVELIN OVARIAN 200 |
|
December 23, 2015 |
March 12, 2018 |
March 12, 2018 |
October 20, 2015 |
January 8, 2018 |
|
- Arizona Oncology Associates, PC - HAL
Chandler, Arizona, United States - Arizona Oncology Associates, PC - HAL
Phoenix, Arizona, United States - Arizona Oncology Associates, PC - HAL
Phoenix, Arizona, United States - (and 285 more...)
|
104 |
NCT00936390 |
Active, not recruiting |
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer |
|
- Drug: bicalutamide
- Drug: buserelin
- Drug: flutamide
- (and 5 more...)
|
Interventional |
Phase 3 |
- Radiation Therapy Oncology Group
- National Cancer Institute (NCI)
- NRG Oncology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Biochemical failure according to the Phoenix (nadir + 2) definition
- Local recurrence
- (and 13 more...)
|
1538 |
Male |
18 Years and older (Adult, Senior) |
NCT00936390 |
RTOG 0815 CDR0000648194 NCI-2011-01948 |
|
September 2009 |
May 2022 |
May 2027 |
July 10, 2009 |
December 26, 2017 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Fairbanks Memorial Hospital
Fairbanks, Alaska, United States - Arizona Center for Cancer Care-Peoria
Peoria, Arizona, United States - (and 515 more...)
|
105 |
NCT00899782 |
Active, not recruiting |
Collection and Storage of Blood and Tissue Samples From Patients Who Are Undergoing Surgery For Lung Cancer |
- Lung Carcinoma
- Lung Neoplasm
- Malignant Lung Neoplasm
|
- Other: cytology specimen collection procedure
|
Observational |
|
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Collection and storage of frozen tissue samples for molecular analysisor resection of lung cancer
- Collection and storage of frozen blood samples for the assessment of somatic mutations and levels of circulating markersto assess levels of circulating markers
|
500 |
All |
18 Years and older (Adult, Senior) |
NCT00899782 |
CALGB-140202 CDR0000271323 U10CA031946 U10CA180821 |
|
July 2004 |
January 2100 |
|
May 12, 2009 |
August 8, 2017 |
|
- Tunnell Cancer Center at Beebe Medical Center
Lewes, Delaware, United States - CCOP - Christiana Care Health Services
Newark, Delaware, United States - Union Hospital of Cecil County
Elkton, Maryland, United States - (and 16 more...)
|
106 |
NCT01347710 |
Completed Has Results |
A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD. |
|
- Drug: Flurpiridaz F18
- Drug: 99mTechnicium (sestamibi or tetrofosmin)
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Diagnostic Efficacy of Flurpiridaz F 18 PET Myocardial Perfusion Imaging (MPI) Sensitivity Versus SPECT Myocardial Perfusion Imaging Sensitivity
- Diagnostic Efficacy of Flurpiridaz PET MPI Specificity Versus SPECT MPI Specificity
- Diagnostic Efficacy of Flurpiridaz F18 PET MPI Sensitivity Versus SPECT MPI Sensitivity in Subgroups: Pharmacologic Stress, Females and BMI>/=30.
- (and 8 more...)
|
795 |
All |
18 Years and older (Adult, Senior) |
NCT01347710 |
BMS747158-301 |
|
June 2011 |
July 2013 |
September 2013 |
May 4, 2011 |
April 5, 2016 |
April 5, 2016 |
- Cardiology Associates of Mobile, Inc.
Mobile, Alabama, United States - Scottsdale Medical Imaging, Ltd.
Scottsdale, Arizona, United States - West Side Medical Associates of Los Angeles
Beverly Hills, California, United States - (and 78 more...)
|
107 |
NCT02194738 |
Recruiting |
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) |
- Large Cell Lung Carcinoma
- Lung Adenocarcinoma
- Stage IB Non-Small Cell Lung Carcinoma AJCC v7
- (and 9 more...)
|
- Other: Cytology Specimen Collection Procedure
- Other: Laboratory Biomarker Analysis
|
Observational |
|
- National Cancer Institute (NCI)
|
NIH |
|
- Central clinical genotyping to facilitate accrual to the adjuvant Intergroup studies, E4512 and A081105, as measured by rate of accrual
- Feasibility of research grade formalin-fixed, paraffin-embedded tissue collection for Center for Cancer Genomics (CCG) analysis, as measured by adequate specimens collected per month
- Disease free survival (DFS) rate for lung cancers which are wild-type for EGFR and ALK
- Agreement of local genotyping methods (direct sequencing of EGFR, ALK fluorescence in situ hybridization [FISH]) with central Clinical Laboratory Improvement Amendments genotyping
|
8300 |
All |
18 Years and older (Adult, Senior) |
NCT02194738 |
NCI-2014-01509 A151216 U10CA180821 U10CA180830 U10CA031946 |
|
August 18, 2014 |
September 28, 2021 |
September 28, 2021 |
July 18, 2014 |
April 20, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - (and 1330 more...)
|
108 |
NCT02193282 |
Recruiting |
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) |
- ALK Gene Rearrangement
- EGFR Exon 19 Deletion Mutation
- EGFR NP_005219.2:p.L858R
- (and 5 more...)
|
- Other: Clinical Observation
- Drug: Erlotinib Hydrochloride
- Other: Laboratory Biomarker Analysis
- Other: Placebo
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Disease free survival (DFS) rate, defined as the proportion of patients alive and disease free at 2 years from the date of randomization
- Overall survival (OS) rate defined as the proportion of patients alive at 5 years from date of randomization
- (and 3 more...)
|
450 |
All |
18 Years and older (Adult, Senior) |
NCT02193282 |
NCI-2014-01508 s16-02079 CALGB A081105 A081105 U10CA180821 U10CA180830 U10CA031946 |
|
August 18, 2014 |
November 4, 2020 |
|
July 17, 2014 |
April 17, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - (and 1302 more...)
|
109 |
NCT02201992 |
Recruiting |
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) |
- ALK Gene Rearrangement
- ALK Gene Translocation
- ALK Positive
- (and 5 more...)
|
- Other: Clinical Observation
- Drug: Crizotinib
- Other: Laboratory Biomarker Analysis
|
Interventional |
Phase 3 |
- ECOG-ACRIN Cancer Research Group
- National Cancer Institute (NCI)
- Eastern Cooperative Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Disease free survival (DFS)
- Toxicity rates, determined using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
|
378 |
All |
18 Years and older (Adult, Senior) |
NCT02201992 |
E4512 NCI-2014-01507 s16-02072 U10CA180820 U10CA180830 U10CA021115 U24CA196172 |
|
August 18, 2014 |
May 1, 2022 |
|
July 28, 2014 |
December 11, 2017 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - (and 1286 more...)
|
110 |
NCT02785952 |
Recruiting |
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers |
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma AJCC v7
|
- Biological: Ipilimumab
- Other: Laboratory Biomarker Analysis
- Biological: Nivolumab
- (and 2 more...)
|
Interventional |
Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Investigator-assessed progression-free survival as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (Design #1, Phase II)
- Less than 33% improvement in median investigator-assessed progression-free survival as defined as Response Evaluation Criteria in Solid Tumors version 1.1 (Design #1, Phase III)
- Overall survival
- (and 4 more...)
|
350 |
All |
18 Years and older (Adult, Senior) |
NCT02785952 |
S1400I NCI-2016-00050 U10CA180888 |
|
December 18, 2015 |
April 1, 2022 |
April 1, 2022 |
May 30, 2016 |
April 10, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 1177 more...)
|
111 |
NCT02785913 |
Active, not recruiting |
S1400B Lung-MAP: Taselisib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches |
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma
|
- Other: Laboratory Biomarker Analysis
- Drug: Taselisib
|
Interventional |
Phase 2 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate (ORR) (confirmed and unconfirmed, complete and partial) (Design #2, Phase II)
- DoR among patients who achieve a CR or PR by RECIST 1.1 (Design #2, Phase II)
- OS with investigational therapy (Design #2, Phase II)
- (and 2 more...)
|
59 |
All |
18 Years and older (Adult, Senior) |
NCT02785913 |
S1400B NCI-2014-01379 U10CA180888 |
|
June 2014 |
June 2017 |
June 2020 |
May 30, 2016 |
July 18, 2017 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 1108 more...)
|
112 |
NCT02965378 |
Active, not recruiting |
Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer |
- FGFR1 Gene Amplification
- FGFR1 Gene Mutation
- FGFR2 Gene Amplification
- (and 5 more...)
|
- Drug: Docetaxel
- Drug: FGFR Inhibitor AZD4547
- Other: Laboratory Biomarker Analysis
|
Interventional |
Phase 2 Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate (confirmed and unconfirmed, complete and partial) (Design #2, Phase II)
- Duration of response among patients who achieve a complete response or partial response by Response Evaluation Criteria in Solid Tumors 1.1 (Design #2, Phase II)
- Overall survival with investigational therapy (Design #2, Phase II)
- (and 2 more...)
|
42 |
All |
25 Years and older (Adult, Senior) |
NCT02965378 |
S1400D NCI-2014-01381 U10CA180888 |
|
June 16, 2014 |
April 1, 2022 |
April 1, 2022 |
November 16, 2016 |
December 15, 2017 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 1081 more...)
|
113 |
NCT02785939 |
Active, not recruiting |
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer |
- CCND1 Gene Amplification
- CCND2 Gene Amplification
- CCND3 Gene Amplification
- (and 3 more...)
|
- Drug: Docetaxel
- Other: Laboratory Biomarker Analysis
- Drug: Palbociclib
|
Interventional |
Phase 2 Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate (confirmed and unconfirmed, complete and partial) (Design #2, Phase II)
- Duration of response among patients who achieve a complete response or partial response by Response Evaluation Criteria in Solid Tumors 1.1 (Design #2, Phase II)
- Overall survival with investigational therapy (Design #2, Phase II)
- (and 2 more...)
|
42 |
All |
18 Years and older (Adult, Senior) |
NCT02785939 |
S1400C NCI-2014-01380 U10CA180888 |
|
June 16, 2014 |
April 1, 2022 |
April 1, 2022 |
May 30, 2016 |
December 15, 2017 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 1062 more...)
|
114 |
NCT01150045 |
Active, not recruiting |
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery |
|
- Drug: celecoxib
- Drug: 5-fluorouracil
- Other: placebo
- (and 2 more...)
|
Interventional |
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Disease-free survival
- Overall survival
|
2500 |
All |
18 Years and older (Adult, Senior) |
NCT01150045 |
CALGB-80702 U10CA031946 CDR0000675693 |
|
June 2010 |
December 2019 |
|
June 24, 2010 |
June 27, 2017 |
|
- University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - Alaska Women's Cancer Care
Anchorage, Alaska, United States - (and 839 more...)
|
115 |
NCT01120249 |
Active, not recruiting |
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery |
|
- Drug: everolimus
- Other: placebo
|
Interventional |
Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Compare Recurrence-free survival in those patients randomized to everolimus versus those randomized to placebo.
- Compare Overall survival in those patients randomized to everolimus versus those randomized to placebo.
- Compare Toxicity between the two study arms
|
1545 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT01120249 |
S0931 U10CA032102 NCI-2011-02028 |
S0931 |
April 2011 |
October 2021 |
October 2021 |
May 10, 2010 |
December 8, 2017 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Gulf Coast MBCCOP
Mobile, Alabama, United States - Providence Hospital
Mobile, Alabama, United States - (and 1000 more...)
|
116 |
NCT00063999 |
Active, not recruiting |
Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer |
- Recurrent Uterine Corpus Carcinoma
- Stage IIIA Uterine Corpus Cancer
- Stage IIIB Uterine Corpus Cancer
- (and 3 more...)
|
- Drug: Carboplatin
- Drug: Cisplatin
- Drug: Doxorubicin Hydrochloride
- (and 5 more...)
|
Interventional |
Phase 3 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Duration of overall survival
- Change in functional well-being assessed using the FACT/GOG Neurotoxicity subscale
- Change in physical well-being assessed using the Functional Assessment of Cancer Therapy (FACT)-Endometrial subscale
- (and 5 more...)
|
1331 |
Female |
18 Years and older (Adult, Senior) |
NCT00063999 |
GOG-0209 NCI-2009-00584 CDR0000305940 U10CA180868 U10CA027469 |
|
August 2003 |
June 2013 |
|
July 9, 2003 |
October 28, 2016 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Clearview Cancer Institute
Huntsville, Alabama, United States - Mobile Infirmary Medical Center
Mobile, Alabama, United States - (and 539 more...)
|
117 |
NCT03377556 |
Recruiting |
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer |
- ATM Gene Mutation
- ATR Gene Mutation
- BARD1 Gene Mutation
- (and 18 more...)
|
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
- Drug: Talazoparib
|
Interventional |
Phase 2 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate assessed by Response Evaluation Criteria in Solid Tumors 1.1 (Design #2)
- Duration of response (Design #2)
- Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Design #2)
- (and 2 more...)
|
64 |
All |
Child, Adult, Senior |
NCT03377556 |
S1400G NCI-2017-00135 U10CA180888 |
|
February 7, 2017 |
May 1, 2022 |
December 2024 |
December 19, 2017 |
April 20, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 1113 more...)
|
118 |
NCT00632853 |
Recruiting |
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide |
|
- Radiation: Standard Radiation Dose Therapy
- Drug: cisplatin
- Drug: etoposide
- (and 2 more...)
|
Interventional |
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival time between 3 treatment arms
- Complete and partial response rates
- Failure-free survival
|
729 |
All |
18 Years and older (Adult, Senior) |
NCT00632853 |
CALGB-30610 RTOG 0538 U10CA031946 CDR0000588879 NCI-2009-00470 |
|
March 2008 |
June 2023 |
|
March 11, 2008 |
April 9, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - The Kirklin Clinic at Acton Road
Birmingham, Alabama, United States - Providence Hospital
Mobile, Alabama, United States - (and 897 more...)
|
119 |
NCT01274338 |
Active, not recruiting |
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery |
- Recurrent Melanoma
- Stage IIIB Cutaneous Melanoma AJCC v7
- Stage IIIC Cutaneous Melanoma AJCC v7
- Stage IV Cutaneous Melanoma AJCC v6 and v7
|
- Biological: Ipilimumab
- Other: Quality-of-Life Assessment
- Biological: Recombinant Interferon Alfa-2b
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- RFS
- OS
- Incidence of toxicity assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- (and 2 more...)
|
1500 |
All |
12 Years and older (Child, Adult, Senior) |
NCT01274338 |
NCI-2011-02649 E1609 ECOG-E1609 CDR0000692568 P50CA121973 U10CA180820 U10CA021115 U24CA196172 |
|
May 25, 2011 |
May 1, 2018 |
|
January 11, 2011 |
April 13, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Providence Hospital
Mobile, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - (and 951 more...)
|
120 |
NCT01570023 |
Completed |
Study of Tongue Strengthening for Swallowing Problems |
|
- Behavioral: Isometric Progressive Resistance Oropharyngeal Therapy
|
Interventional |
Not Applicable |
- University of Wisconsin, Madison
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Swallow Function
- Change in Penetration/Aspiration Scale score
- Change in Residue Scale score
- (and 3 more...)
|
34 |
All |
21 Years to 95 Years (Adult, Senior) |
NCT01570023 |
2011-0518 |
|
April 2012 |
September 2015 |
September 2015 |
April 4, 2012 |
October 12, 2015 |
|
- Northwestern University
Evanston, Illinois, United States - Central Baptist Hospital
Lexington, Kentucky, United States - Minneapolis Veterans Administration Health Care System
Minneapolis, Minnesota, United States - (and 6 more...)
|
121 |
NCT01835158 |
Active, not recruiting |
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer |
- Clear Cell Renal Cell Carcinoma
- Metastatic Renal Cell Cancer
- Stage III Renal Cell Cancer AJCC v7
- Stage IV Renal Cell Cancer AJCC v7
|
- Drug: Cabozantinib S-malate
- Other: Laboratory Biomarker Analysis
- Drug: Sunitinib Malate
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (PFS)
- Overall survival (OS)
- Objective response rates
- Proportion of patients with unacceptable treatment related grade 3 or higher toxicity for all patients assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
|
158 |
All |
18 Years and older (Adult, Senior) |
NCT01835158 |
NCI-2013-00820 A031203 U10CA180821 U10CA031946 |
|
July 8, 2013 |
April 18, 2016 |
|
April 18, 2013 |
April 13, 2018 |
|
- Southern Cancer Center PC-Providence
Mobile, Alabama, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - Alaska Women's Cancer Care
Anchorage, Alaska, United States - (and 487 more...)
|
122 |
NCT02766335 |
Active, not recruiting |
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers |
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma AJCC v7
|
- Drug: Docetaxel
- Biological: Durvalumab
- Other: Laboratory Biomarker Analysis
|
Interventional |
Phase 2 Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate (confirmed and unconfirmed, complete and partial), as defined by Response Evaluation Criteria in Solid Tumors 1.1
- Investigator-assessed progression-free survival all patients and the subset of PD-L1 positive patients, as defined by Response Evaluation Criteria in Solid Tumors criteria
- Investigator-assessed progression-free survival assessed using a modified response criteria adapted for immunotherapy
- (and 2 more...)
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT02766335 |
S1400A NCI-2014-01378 U10CA180888 |
|
June 16, 2014 |
April 1, 2022 |
April 1, 2022 |
May 9, 2016 |
December 15, 2017 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 990 more...)
|
123 |
NCT00946712 |
Active, not recruiting |
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer |
- Recurrent Large Cell Lung Carcinoma
- Recurrent Lung Adenocarcinoma
- Recurrent Squamous Cell Lung Carcinoma
- (and 3 more...)
|
- Biological: Bevacizumab
- Drug: Carboplatin
- Biological: Cetuximab
- (and 2 more...)
|
Interventional |
Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Progression-free survival (PFS) of EGFR FISH-positive patients by institutional review
- Incidence of toxicity as assessed by NCI CTCAE version 4.0
- (and 4 more...)
|
1546 |
All |
18 Years and older (Adult, Senior) |
NCT00946712 |
S0819 NCI-2009-01664 CDR0000649817 U10CA180888 U10CA032102 |
|
July 2009 |
August 31, 2017 |
August 31, 2018 |
July 27, 2009 |
October 5, 2017 |
|
- Northeast Alabama Regional Medical Center
Anniston, Alabama, United States - Gulf Coast MBCCOP
Mobile, Alabama, United States - Providence Hospital
Mobile, Alabama, United States - (and 795 more...)
|
124 |
NCT00942331 |
Active, not recruiting |
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer |
- Bladder Urothelial Carcinoma
- Distal Urethral Carcinoma
- Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma
- (and 11 more...)
|
- Biological: Bevacizumab
- Drug: Cisplatin
- Drug: Gemcitabine Hydrochloride
- (and 2 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Progression-free survival (PFS)
- Objective response rate (defined as confirmed complete and partial responses) using Response Evaluation Criteria in Solid Tumors criteria
- Grade 3 or greater treatment-related toxicity using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
|
500 |
All |
18 Years and older (Adult, Senior) |
NCT00942331 |
NCI-2011-01952 CDR0000649174 CALGB-90601 U10CA180821 U10CA031946 |
|
July 15, 2009 |
June 30, 2019 |
|
July 20, 2009 |
April 13, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Providence Hospital
Mobile, Alabama, United States - Fairbanks Memorial Hospital
Fairbanks, Alaska, United States - (and 873 more...)
|
125 |
NCT01886872 |
Active, not recruiting |
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia |
- CD19 Positive
- CD20 Positive
- CD5 Positive
- (and 4 more...)
|
- Drug: Bendamustine Hydrochloride
- Drug: Ibrutinib
- Other: Laboratory Biomarker Analysis
- (and 2 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (PFS)
- Overall survival (OS)
- Time to progression
- (and 11 more...)
|
523 |
All |
65 Years and older (Adult, Senior) |
NCT01886872 |
NCI-2013-01220 ALLIANCE A041202 A041202 K23CA178183 R01CA183444 U10CA180821 U10CA031946 |
|
December 9, 2013 |
May 16, 2018 |
|
June 26, 2013 |
April 13, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 952 more...)
|
126 |
NCT00588770 |
Active, not recruiting |
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
- Recurrent Hypopharyngeal Squamous Cell Carcinoma
- Recurrent Laryngeal Squamous Cell Carcinoma
- Recurrent Laryngeal Verrucous Carcinoma
- (and 33 more...)
|
- Biological: Bevacizumab
- Drug: Carboplatin
- Drug: Cisplatin
- (and 3 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Comorbidities
- Incidence of toxicity as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- (and 2 more...)
|
400 |
All |
18 Years and older (Adult, Senior) |
NCT00588770 |
NCI-2009-00507 CDR0000582533 E1305 U10CA180820 U10CA021115 |
|
August 8, 2008 |
February 28, 2018 |
|
January 9, 2008 |
March 2, 2018 |
|
- Providence Hospital
Mobile, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Fairbanks Memorial Hospital
Fairbanks, Alaska, United States - (and 791 more...)
|
127 |
NCT01015833 |
Active, not recruiting |
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer |
- Advanced Adult Hepatocellular Carcinoma
- Non-Resectable Hepatocellular Carcinoma
- Recurrent Hepatocellular Carcinoma
- (and 7 more...)
|
- Drug: Doxorubicin Hydrochloride
- Other: Laboratory Biomarker Analysis
- Other: Pharmacogenomic Study
- Drug: Sorafenib Tosylate
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Overall survival
- Incidence of adverse events, as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Progression free survival
|
360 |
All |
18 Years and older (Adult, Senior) |
NCT01015833 |
NCI-2011-01989 CDR0000659348 CALGB-80802 U10CA180821 U10CA031946 |
|
February 15, 2010 |
May 21, 2015 |
|
November 18, 2009 |
August 23, 2017 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Providence Hospital
Mobile, Alabama, United States - Southern Cancer Center PC-Providence
Mobile, Alabama, United States - (and 621 more...)
|
128 |
NCT00803062 |
Completed Has Results |
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer |
- Cervical Adenocarcinoma
- Cervical Adenosquamous Carcinoma
- Cervical Squamous Cell Carcinoma
- (and 2 more...)
|
- Biological: Bevacizumab
- Drug: Cisplatin
- Other: Laboratory Biomarker Analysis
- (and 4 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival
- Progression-free Survival
- Tumor Response
- To Determine and Compare the Frequency and Severity of Adverse Events as Assessed by CTCAE Version 3.0 for the Regimens Administered on This Study.
|
452 |
Female |
18 Years and older (Adult, Senior) |
NCT00803062 |
NCI-2009-01084 CDR0000628746 GOG-0240 U10CA180868 U10CA027469 |
|
April 2009 |
February 2013 |
February 2013 |
December 5, 2008 |
December 7, 2017 |
May 24, 2016 |
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Saint Joseph's Hospital and Medical Center
Phoenix, Arizona, United States - (and 546 more...)
|
129 |
NCT00324805 |
Active, not recruiting Has Results |
Chemotherapy With or Without Bevacizumab in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer |
- Stage IB Non-Small Cell Lung Carcinoma
- Stage IIA Non-Small Cell Lung Carcinoma
- Stage IIB Non-Small Cell Lung Carcinoma
- Stage IIIA Non-small Cell Lung Cancer
|
- Biological: Bevacizumab
- Drug: Cisplatin
- Drug: Docetaxel
- (and 3 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
- Cancer and Leukemia Group B
- NCIC Clinical Trials Group
- (and 2 more...)
|
NIH / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival
- Disease-free Survival
|
1501 |
All |
18 Years and older (Adult, Senior) |
NCT00324805 |
NCI-2009-00509 CDR0000475774 E1505 U10CA180820 U10CA021115 |
|
June 1, 2007 |
October 20, 2015 |
October 16, 2023 |
May 11, 2006 |
February 14, 2018 |
February 14, 2018 |
- Northeast Alabama Regional Medical Center
Anniston, Alabama, United States - Clearview Cancer Institute
Huntsville, Alabama, United States - Providence Hospital
Mobile, Alabama, United States - (and 1097 more...)
|
130 |
NCT00079274 |
Completed Has Results |
Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer |
- Adenocarcinoma of the Colon
- Stage III Colon Cancer
|
- Drug: irinotecan hydrochloride
- Drug: oxaliplatin
- Drug: leucovorin calcium
- (and 3 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
- Eastern Cooperative Oncology Group
|
NIH / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-free Survival (Arms A and D: Wild-type KRAS Patients)
- Disease-free Survival (Arms A and D: Mutant KRAS Patients)
- Disease-free Survival
- (and 2 more...)
|
3397 |
All |
18 Years and older (Adult, Senior) |
NCT00079274 |
NCI-2009-00639 N0147 U10CA025224 CDR0000355132 |
|
February 2004 |
November 2012 |
November 2012 |
March 10, 2004 |
February 9, 2015 |
February 9, 2015 |
- Northeast Alabama Regional Medical Center
Anniston, Alabama, United States - Clearview Cancer Institute
Huntsville, Alabama, United States - Mobile Infirmary Medical Center
Mobile, Alabama, United States - (and 891 more...)
|
131 |
NCT01349881 |
Recruiting |
S0820, Adenoma and Second Primary Prevention Trial |
|
- Drug: Eflornithine placebo & sulindac placebo
- Drug: eflornithine & sulindac placebo
- Drug: Eflornithine placebo & sulindac
- Drug: Eflornithine plus sulindac
|
Interventional |
Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Cancer Prevention Pharmaceuticals, Inc.
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- 3-year event rate after registration among Stage 0-III colon cancer patients. (An event is defined as high-risk adenoma or second primary colorectal cancer.)
- Incidence of colorectal lesions with respect to high-grade dysplasia, adenomas with villous features, adenomas 1 cm or greater, multiple adenomas, polyps >/= 0.3 cm, total advanced colorectal events or total colorectal events at 3 years.
- Toxicity by CTCAEv.4.0 at 3 years
- (and 3 more...)
|
1340 |
All |
18 Years and older (Adult, Senior) |
NCT01349881 |
S0820 U10CA037429 NCI-2012-02067 |
PACES |
March 2013 |
June 2024 |
June 2029 |
May 9, 2011 |
March 21, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 922 more...)
|
132 |
NCT00430183 |
Active, not recruiting |
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer |
|
- Drug: docetaxel
- Drug: LHRH agonist
- Procedure: surgery
|
Interventional |
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Eastern Cooperative Oncology Group
- (and 2 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 3-year biochemical progression-free survival (bPFS) rate
- 5-year bPFS rate and bPFS
- Time to clinical local recurrence (The time from randomization to the first biopsy-proven recurrence in the prostatic bed or new mass.)
- (and 5 more...)
|
788 |
Male |
18 Years and older (Adult, Senior) |
NCT00430183 |
CALGB 90203 U10CA031946 CDR0000526353 |
|
December 2006 |
June 2018 |
|
February 1, 2007 |
June 27, 2017 |
|
- Providence Cancer Center
Anchorage, Alaska, United States - Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
Fairbanks, Alaska, United States - Alta Bates Summit Comprehensive Cancer Center
Berkeley, California, United States - (and 223 more...)
|
133 |
NCT02890355 |
Active, not recruiting |
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer |
- Metastatic Pancreatic Adenocarcinoma
- Recurrent Pancreatic Carcinoma
- Stage IV Pancreatic Cancer AJCC v6 and v7
|
- Drug: Fluorouracil
- Drug: Irinotecan Hydrochloride
- Other: Laboratory Biomarker Analysis
- (and 2 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Incidence of adverse events associated with each treatment arm using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Progression free survival (PFS)
- (and 3 more...)
|
143 |
All |
18 Years and older (Adult, Senior) |
NCT02890355 |
NCI-2015-02248 S1513 U10CA180888 |
|
September 1, 2016 |
May 1, 2019 |
|
September 7, 2016 |
April 13, 2018 |
|
- University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 792 more...)
|
134 |
NCT01863550 |
Recruiting |
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma |
|
- Drug: Bortezomib
- Drug: Carfilzomib
- Drug: Dexamethasone
- (and 3 more...)
|
Interventional |
Phase 3 |
- ECOG-ACRIN Cancer Research Group
- National Cancer Institute (NCI)
- Eastern Cooperative Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS) for the maintenance analysis
- Progression-free survival for the induction analysis
- Change in the FACT-Ntx TOI for the early induction analysis
- (and 16 more...)
|
1080 |
All |
18 Years and older (Adult, Senior) |
NCT01863550 |
E1A11 NCI-2012-02608 ECOG-E1A11 s17-00040 U10CA180820 U10CA021115 U24CA196172 |
|
December 2, 2013 |
November 1, 2023 |
|
May 29, 2013 |
January 30, 2018 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Mercy Cancer Center-Hot Springs
Hot Springs, Arkansas, United States - Veteran's Administration Medical Center
Little Rock, Arkansas, United States - (and 843 more...)
|
135 |
NCT00849667 |
Completed |
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse |
|
- Drug: MORAb-003 (farletuzumab)
- Drug: 0.9% Saline
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Progression-free survival using by RECIST
- Overall Survival, CA-125 PFS, GCIG PFS, Length of first versus second remission, Tumor Response,Serologic Response (CA-125), Quality of Life, Resource utilization and PK DDI substudy.
|
1100 |
Female |
18 Years and older (Adult, Senior) |
NCT00849667 |
MORAb003-004 |
|
April 2009 |
December 2012 |
April 2013 |
February 24, 2009 |
July 20, 2015 |
|
- University Of Alabama At Birmingham
Birmingham, Alabama, United States - Oncology Specialties, PC
Huntsville, Alabama, United States - Arizona Hematology & Oncology Associates
Phoenix, Arizona, United States - (and 372 more...)
|
136 |
NCT02595944 |
Recruiting |
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) |
- Stage IB Non-Small Cell Lung Carcinoma AJCC v7
- Stage II Non-Small Cell Lung Cancer AJCC v7
- Stage IIA Non-Small Cell Lung Carcinoma AJCC v7
- (and 2 more...)
|
- Other: Laboratory Biomarker Analysis
- Biological: Nivolumab
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Disease-free survival
- Incidence of toxicity graded according to Common Terminology Criteria for Adverse Events version 4.0
|
714 |
All |
18 Years and older (Adult, Senior) |
NCT02595944 |
NCI-2015-01916 EA5142 s16-02074 U10CA180820 |
ANVIL |
May 6, 2016 |
July 1, 2024 |
|
November 4, 2015 |
April 18, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - (and 729 more...)
|
137 |
NCT00689936 |
Completed Has Results |
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma |
|
- Drug: Lenalidomide and low-dose dexamethasone
- Drug: Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles
- Drug: Melphalan, Prednisone and Thalidomide
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Kaplan-Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Independent Review Adjudication Committee (IRAC)
- Kaplan-Meier Estimates of PFS Based on the Response Assessment by the Investigator At the Time of Final Analysis
- Kaplan Meier Estimates of Overall Survival at the Time of Final Analysis (OS)
- (and 42 more...)
|
1623 |
All |
18 Years and older (Adult, Senior) |
NCT00689936 |
CC-5013-MM-020 2007-004823-39 |
FIRST |
August 21, 2008 |
July 14, 2016 |
July 14, 2016 |
June 4, 2008 |
October 19, 2017 |
August 11, 2017 |
- University of AL Birmingham
Birmingham, Alabama, United States - Cedar Sinai Medical Center Dept of Medicine
Los Angeles, California, United States - University of California, San Francisco- California
San Francisco, California, United States - (and 296 more...)
|
138 |
NCT02834013 |
Recruiting |
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
- Acinar Cell Carcinoma
- Adenoid Cystic Carcinoma
- Adrenal Cortex Carcinoma
- (and 82 more...)
|
- Procedure: Biospecimen Collection
- Biological: Ipilimumab
- Biological: Nivolumab
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate (ORR) defined as confirmed and unconfirmed complete and partial response
- Incidence of adverse events graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- Best response calculated from the sequence of RECIST 1.1 and immune-related response criteria (irRC) objectives
- (and 3 more...)
|
707 |
All |
18 Years and older (Adult, Senior) |
NCT02834013 |
NCI-2016-01041 S1609 U10CA180888 |
|
January 13, 2017 |
August 31, 2020 |
|
July 15, 2016 |
April 17, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - (and 815 more...)
|
139 |
NCT00000790 |
Completed |
Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection |
- HIV Infections
- Stomatitis, Aphthous
|
|
Interventional |
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- Andrulis Pharmaceuticals
|
NIH / Industry |
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
|
|
164 |
All |
13 Years and older (Child, Adult, Senior) |
NCT00000790 |
ACTG 251 11228 |
|
|
|
October 1998 |
August 31, 2001 |
April 3, 2012 |
|
- Univ of Alabama at Birmingham
Birmingham, Alabama, United States - Univ of Southern California / LA County USC Med Ctr
Los Angeles, California, United States - San Francisco AIDS Clinic / San Francisco Gen Hosp
San Francisco, California, United States - (and 37 more...)
|
140 |
NCT02154490 |
Recruiting |
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer |
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma AJCC v7
|
- Drug: Docetaxel
- Biological: Durvalumab
- Drug: Erlotinib Hydrochloride
- (and 10 more...)
|
Interventional |
Phase 2 Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Investigator-assessed progression-free survival as defined by Response Evaluation Criteria in Solid Tumors 1.1 (Design #1, Phase II)
- Investigator-assessed progression-free survival in patients with advanced stage refractory squamous cell carcinoma of the lung randomized to receive investigational therapy vs standard therapy (Design #2,Phase III,Option for Biomarker-driven sub-studies)
- Less than 33% improvement in median investigator-assessed progression-free survival as defined as Response Evaluation Criteria in Solid Tumors 1.1 (Design #1, Phase III)
- (and 13 more...)
|
10000 |
All |
18 Years and older (Adult, Senior) |
NCT02154490 |
S1400 NCI-2014-00627 S1400A S1400E S1400I S1400C S1400D S1400B U10CA180888 |
|
June 16, 2014 |
April 1, 2022 |
April 1, 2022 |
June 3, 2014 |
March 21, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 972 more...)
|
141 |
NCT00433511 |
Active, not recruiting |
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer |
- Estrogen Receptor Negative
- Estrogen Receptor Positive
- HER2/Neu Negative
- (and 8 more...)
|
- Biological: Bevacizumab
- Drug: Cyclophosphamide
- Drug: Doxorubicin Hydrochloride
- (and 4 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
- Cancer and Leukemia Group B
- Eastern Cooperative Oncology Group
- North Central Cancer Treatment Group
|
NIH / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-free survival
- Incidence of adverse events graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0
- Overall survival
- Quality of life, measured by average total score for the Functional Assessment of Cancer Therapy-Breast
|
4890 |
All |
18 Years and older (Adult, Senior) |
NCT00433511 |
NCI-2009-00561 E5103 ECOG-E5103 CDR0000528955 U10CA180820 U10CA021115 |
|
November 2, 2007 |
September 30, 2016 |
|
February 12, 2007 |
October 11, 2017 |
|
- Northeast Alabama Regional Medical Center
Anniston, Alabama, United States - University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Providence Hospital
Mobile, Alabama, United States - (and 812 more...)
|
142 |
NCT02111564 |
Recruiting |
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients |
- Heart Failure
- Respiratory Insufficiency
- Stroke Acute
- (and 2 more...)
|
- Drug: Rivaroxaban, 10 mg
- Drug: Rivaroxaban, 7.5 mg
- Drug: Placebo
|
Interventional |
Phase 3 |
- Janssen Research & Development, LLC
- Bayer
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Prevention
|
- Time from randomization to the first occurrence of symptomatic venous thromboembolism event (VTE) and VTE-related death
- Time from randomization to the first occurrence of major bleeding
- Time from randomization to an occurrence of VTE-related death
- (and 6 more...)
|
12000 |
All |
40 Years and older (Adult, Senior) |
NCT02111564 |
CR103834 2014-000305-13 RIVAROXDVT3002 |
MARINER |
June 2, 2014 |
May 25, 2018 |
May 25, 2018 |
April 11, 2014 |
April 9, 2018 |
|
- Achieve Clinical Research, LLC
Birmingham, Alabama, United States - The Heart Center, PC - Huntsville Hospital
Huntsville, Alabama, United States - Mobile Heart Specialists, PC
Mobile, Alabama, United States - (and 1501 more...)
|
143 |
NCT01120236 |
Completed Has Results |
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer |
- Prostate Adenocarcinoma
- Recurrent Prostate Carcinoma
- Stage IV Prostate Cancer
|
- Drug: Bicalutamide
- Biological: Cixutumumab
- Drug: Goserelin Acetate
- (and 3 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Undetectable PSA Rate
- Toxicity
- Proportion of Patients Who do Not Achieve a Partial PSA Response
- (and 4 more...)
|
211 |
Male |
18 Years and older (Adult, Senior) |
NCT01120236 |
NCI-2011-02003 SWOG-S0925 CDR0000663832 S0925 U10CA032102 |
|
December 2010 |
June 2015 |
August 23, 2017 |
May 10, 2010 |
February 26, 2018 |
October 6, 2016 |
- Fairbanks Memorial Hospital
Fairbanks, Alaska, United States - University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - Highlands Oncology Group-Rogers
Rogers, Arkansas, United States - (and 167 more...)
|
144 |
NCT00499330 |
Active, not recruiting |
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer |
|
- Procedure: lobectomy
- Procedure: segmentectomy or wedge resection
|
Interventional |
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- disease-free survival
- overall survival
- rate of loco-regional and systemic recurrence
- pulmonary function as measured by expiratory flow rate 6 months postoperatively
|
701 |
All |
18 Years and older (Adult, Senior) |
NCT00499330 |
CALGB 140503 CALGB-140503 CDR0000555324 NCI-2009-00447 |
|
June 2007 |
March 2021 |
|
July 11, 2007 |
May 30, 2017 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 383 more...)
|
145 |
NCT01674140 |
Recruiting |
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer |
|
- Drug: anastrozole
- Drug: everolimus
- Drug: exemestane
- (and 5 more...)
|
Interventional |
Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- IDFS using a stratified log-rank test, assessed up to 10 years
- OS estimates will be based on Kaplan-Meier procedures, assessed up to 10 years
- DRFS, assessed up to 10 years
- Toxicity based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, assessed up to 10 years
|
1900 |
All |
18 Years and older (Adult, Senior) |
NCT01674140 |
S1207 U10CA032102 NCI-2012-01995 |
e3 |
April 2013 |
December 2022 |
January 2030 |
August 28, 2012 |
March 21, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 1432 more...)
|
146 |
NCT00217737 |
Active, not recruiting |
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer |
- Colon Mucinous Adenocarcinoma
- Colon Signet Ring Cell Adenocarcinoma
- Lynch Syndrome
- (and 3 more...)
|
- Biological: Bevacizumab
- Drug: Fluorouracil
- Other: Laboratory Biomarker Analysis
- (and 2 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-free survival
- Overall survival
- Incidence of adverse events graded by NCI CTCAE 4.0
- Impact of tumor biologic characteristics and their relationship to overall survival
|
3610 |
All |
18 Years and older (Adult, Senior) |
NCT00217737 |
NCI-2009-00562 ECOG-E5202 E5202 CDR0000443410 05-198 U10CA180820 U10CA021115 |
|
August 4, 2005 |
June 30, 2018 |
|
September 22, 2005 |
April 20, 2018 |
|
- Northeast Alabama Regional Medical Center
Anniston, Alabama, United States - University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Clearview Cancer Institute
Huntsville, Alabama, United States - (and 935 more...)
|
147 |
NCT00326898 |
Completed Has Results |
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery |
- Stage I Renal Cell Cancer
- Stage II Renal Cell Cancer
- Stage III Renal Cell Cancer
|
- Other: Placebo
- Drug: Sorafenib
- Drug: Sunitinib
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
- ECOG-ACRIN Cancer Research Group
- NCIC Clinical Trials Group
- (and 2 more...)
|
NIH / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Disease-free Survival (DFS)
- 5-year Overall Survival Rate
- Proportion of Patients With Cardiac Events
- 5-year Disease-free Survival (DFS) Rate Among Patients With Clear Cell Histology
|
1943 |
All |
18 Years and older (Adult, Senior) |
NCT00326898 |
NCI-2009-00534 E2805 U10CA023318 |
ASSURE |
April 2006 |
December 2010 |
August 2015 |
May 17, 2006 |
February 8, 2017 |
December 12, 2016 |
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Clearview Cancer Institute
Huntsville, Alabama, United States - Mobile Infirmary Medical Center
Mobile, Alabama, United States - (and 918 more...)
|
148 |
NCT01515787 |
Recruiting |
PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery |
|
- Drug: FOLFOX (chemotherapy)
- Other: 5 FUCMT (chemoradiation)
- Procedure: surgery
- Procedure: magnetic resonance imaging or endorectal ultrasound
|
Interventional |
Phase 2 Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pelvic R0 resection rate (Phase II)
- DFS (Phase III)
- Time to local recurrence (TLR)
- (and 4 more...)
|
1120 |
All |
18 Years and older (Adult, Senior) |
NCT01515787 |
N1048 CDR0000715321 NCI-2012-00234 U10CA031946 |
|
January 2012 |
January 2021 |
|
January 24, 2012 |
April 9, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - (and 1030 more...)
|
149 |
NCT01272037 |
Active, not recruiting |
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer |
- Ductal Breast Carcinoma In Situ
- Estrogen Receptor and/or Progesterone Receptor Positive
- HER2/Neu Negative
- (and 4 more...)
|
- Drug: Anastrozole
- Drug: Exemestane
- Other: Laboratory Biomarker Analysis
- (and 4 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- RS, as measured by Oncotype DX
- OS
- DDFS
- (and 2 more...)
|
10000 |
Female |
18 Years and older (Adult, Senior) |
NCT01272037 |
NCI-2011-02623 CDR0000692475 PS1007_A11PAMDREVW01 SWOG-S1007 S12-03603 S1007 U10CA180830 U10CA180888 U10CA032102 |
|
January 15, 2011 |
February 1, 2022 |
|
January 7, 2011 |
April 20, 2018 |
|
- Northeast Alabama Regional Medical Center
Anniston, Alabama, United States - University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Gulf Coast MBCCOP
Mobile, Alabama, United States - (and 1588 more...)
|
150 |
NCT01041781 |
Terminated |
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer |
|
- Drug: carboplatin
- Drug: celecoxib
- Drug: gemcitabine hydrochloride
- (and 2 more...)
|
Interventional |
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Progression-free survival
- Overall survival
- Response rate
- (and 3 more...)
|
313 |
All |
18 Years and older (Adult, Senior) |
NCT01041781 |
CALGB-30801 CDR0000662707 |
|
February 2010 |
November 2013 |
December 2016 |
January 1, 2010 |
August 10, 2017 |
|
- Regional Medical Center
Anniston, Alabama, United States - Mayo Clinic Scottsdale
Scottsdale, Arizona, United States - NEA Medical Clinic - East Matthews
Jonesboro, Arkansas, United States - (and 397 more...)
|